We are all a bit jaded. All these "breakthroughs" amounted to so little as the greater market just refused to support the stock. It was claimed that Aussie market does not understand us but Nasdaq is not particularly keen on us either. Ultimately management needs to take responsibility as they would take credit if the share price is sky rocketing. Just a bit of minor adjustments Caods, the case Phantom referred to was probably the ViViV , not just ViV. Also in his Tweets/X, Chris Meduri states that the TMVR was introduced via a transseptal approach via a little cut through the foramen ovale and not through he aorta. Yes they did flip the valve which is quite clever but I guess Edwards had tried this approach with their valve too. I can't read the echo recording but the responses to his X from interventional cardiolgists suggest the outcome was outstanding. I would have though the company would be excited by this and would put some fuel under the share price. BTW what is the TAM of TMVR?
AVR Price at posting:
$6.31 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)